A new 108,000-square-foot testing facility in Chengdu, China, will allow WuXi AppTec to help meet high global demand for toxicology testing in preclinical studies.
The facility significantly expands WuXi AppTec’s testing capacity at a time when many customers’ preclinical studies are facing supply-chain related delays. The pharmaceutical supply chain has faced significant stress in the form of materials scarcity, long lead times, high costs and regulatory restrictions—much of which was only exacerbated by the pandemic.
The pharmaceutical industry has a particularly challenging set of supply chain dynamics, making efficient logistics management a key competitive advantage. WuXi AppTec’s expanded testing capacity ensures that it is in an excellent position to meet its global customers’ needs.
The additional capacity and capabilities created by the Chengdu expansion ensures WuXi AppTec can offer enhanced service, less wait time and a faster start for preclinical studies, and the ability to keep toxicology programs on track.
The new facility features state-of-the-art testing equipment including an automatic hematology analyzer, automatic biochemical analyzer, automatic coagulation analyzer, flow cytometer, LCMS/MS and UPLC.
The expanded footprint reinforces WuXi AppTec’s position as the largest toxicology platform in Asia Pacific, with capabilities that include:
- Discovery: genetox, general tox, ocular PD
- IND-enabling: genetox, general tox, safety pharm, ocular tox
- NDA-enabling: general tox, carcinogenicity, DART, ocular tox
- Post-NDA: adverse effect investigative-type and post-market commitment studies
WuXi AppTec provides a full range of safety assessment services for preclinical and clinical stage studies along with bioanalytical services and informatics management services that promise greater efficiency for reporting and sending test results. These added capabilities make WuXi AppTec a turnkey solution for customers. And when it comes to global sample shipping, WuXi AppTec offers a one-stop service and expedited customs clearance.
WuXi AppTec toxicology facilities meet full regulatory compliance requirements, including full AAALAC accreditation, NMPA GLP certification, OCED inspection and U.S. FDA inspection.
Check out the laboratory testing division blog for more information on WuXi AppTec developments and capabilities.
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,600 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.”
